Volume 10, Number 4—April 2004
Research
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Emily L.C. Tan*, Eng Eong Ooi†, Chin-Yo Lin*, Hwee Cheng Tan†, Ai Ee Ling‡, Bing Lim*, and Lawrence W. Stanton*
Table 1
Commercially available antiviral agents tested, source and starting concentration
| Antiviral agent | Source | Highest concentration tested | Inhibition of cytopathic effect (CIA100) |
|---|---|---|---|
| Interferons |
|||
| Interferon α-2a (Roferon) |
Roche |
100,000 IU/mL |
No |
| Interferon α-2b (Intron A) |
Schering-Plough |
500,000 IU/mL |
No |
| Interferon α-n1 (Wellferon) |
GlaxoSmithKline |
500,000 IU/mL |
Yes |
| Interferon α-n3 (Alferon) |
Hemispheryx |
10,000 IU/mL |
Yes |
| Interferon β-1a (Rebif) |
Serono |
500,000 IU/mL |
No |
| Interferon β-1b (Betaferon) |
Schering AG |
100,000 IU/mL |
Yes |
| Nucleoside analogs |
|||
| Acyclovir |
Faulding |
1,000 μg/ml |
No |
| Cymevene (Ganciclovir) |
Roche |
50,000 μg/mL |
No |
| Ribavirin |
ICN Pharma |
10,000 μg/mL |
Yes |
| Protease inhibitors |
|||
| Indinavir (Crixivan) |
Merck |
100 μM |
No |
| Nelfinavir (Viracept) |
Roche |
10,000 nM |
No |
| Saquinavir (Fortovase) |
Roche |
10,000 nM |
No |
| Reverse transcriptase inhibitors |
|||
| Lamivudine (Epivir) |
GlaxoSmithKline |
1,000 μM |
No |
| Zidovudine (Retrovir) |
GlaxoSmithKline |
1,000 μg/mL |
No |
| Neuraminidase inhibitors |
|||
| Oseltamivir (Tamiflu) |
Roche |
10,000 μM |
No |
| Zanamivir (Relenza) |
GlaxoSmithKline |
1,000 μM |
No |
| Other |
|||
| Amantadine (Symmetrel) |
Novartis |
1,000 μg/mL |
No |
| Foscarnet (Foscavir) | AstraZeneca | 8,000 μM | No |
Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.